secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2022-02-03T23:59:59+00:00
Accession:  0001159036-22-000005
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CFO Elaine Sun steps down; Nicole LaBrosse appointed effective Feb 2, 2022
--------------------------------------------------------------------------

- Elaine Sun left immediately to pursue another opportunity; separation agreement expected.
- Nicole LaBrosse, previously VP Finance and Accounting since 2020, named CFO.
- LaBrosse's initial base salary set at $485,500 with 45% bonus target.
- LaBrosse has 18+ years of public accounting and corporate finance experience, including at PwC.
- CEO Dr. Helen Torley highlighted LaBrosse's internal knowledge and financial skill set.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903622000005/0001159036-22-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903622000005/halo-20220202.htm
  HTML page:      https://secwatch.observer/filing/0001159036-22-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer